AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12135220 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral angle measurement
Number of subjects: 73
Study 12135220 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethrovesical mobility measurement
Number of subjects: 73
Study 12135220 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound variables comparison
Number of subjects: 73
Study 11763255 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular viewing condition
Number of subjects: 0
Study 11763255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate fixation with no binocular time
Number of subjects: 0
Study 11763255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate fixation with binocular time
Number of subjects: 0
Study 9250553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AFF
Number of subjects: 30
Study 9250553 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8341893 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 11
Study 3767432 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde exposure
Number of subjects: 15
Study 3767432 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm formaldehyde exposure with moderate exercise
Number of subjects: 15
Study 30319663 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinomenine (SIN)
Number of subjects: 0
Study 30319663 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 0
Study 27716152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol (maximum dose: 12.5 mg/day)
Number of subjects: 250
Study 27716152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 27716152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose carvedilol
Number of subjects: 250
Study 26985269 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone 'beep' intervention (short phone call not picked up)
Number of subjects: 471
Study 26985269 — intervention group
Group type: COMPARATOR
Intervention: Control group (return to health facility for reporting)
Number of subjects: 471
Study 23148885 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 34
Study 23148885 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 34
Study 21909371 — intervention group
Group type: EXPERIMENTAL
Intervention: Betel quid intoxication
Number of subjects: 12
Study 18214504 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 101
Study 18214504 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 101
Study 17009838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid group (Bronchicum Elixir S, 6 x 5 ml daily)
Number of subjects: 189
Study 17009838 — intervention group
Group type: COMPARATOR
Intervention: Drops group (Bronchcium Tropfen, 5 x 1 ml daily)
Number of subjects: 189
Study 17009838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid group
Number of subjects: 189
Study 17009838 — intervention group
Group type: COMPARATOR
Intervention: Drops group
Number of subjects: 189
Study 17009838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 189
Study 14759070 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 (100 microg daily)
Number of subjects: 108
Study 14759070 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (25 microg daily)
Number of subjects: 108
Study 14759070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 11072156 — intervention group
Group type: EXPERIMENTAL
Intervention: C-RT (cisplatinum 40 mg/m(2)/weekly + radiation therapy)
Number of subjects: 8
Study 11072156 — intervention group
Group type: COMPARATOR
Intervention: RT (radiation therapy alone)
Number of subjects: 8
Study 11072156 — intervention group
Group type: EXPERIMENTAL
Intervention: C-RT
Number of subjects: 8
Study 11072156 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 8
Study 8821843 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐flux biocompatible (BCM) membrane
Number of subjects: 159
Study 8821843 — intervention group
Group type: COMPARATOR
Intervention: Low‐flux bioincompatible (BICM) membrane
Number of subjects: 159
Study 1385010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin (7 x 10(6) KIU)
Number of subjects: 50
Study 1385010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of aprotinin (2 x 10(6) KIU)
Number of subjects: 50
Study 1385010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1385010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin
Number of subjects: 50
Study 1385010 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-dose aprotinin and Single bolus of aprotinin
Number of subjects: 50
Study 30296887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered Carotid Stents (TCS)
Number of subjects: 148
Study 30296887 — intervention group
Group type: COMPARATOR
Intervention: Straight Carotid Stents (SCS)
Number of subjects: 148
Study 27480757 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10(10) colony-forming units of Lactobacillus rhamnosus GG, twice daily
Number of subjects: 150
Study 27480757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24595780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100
Study 24595780 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture (placebo)
Number of subjects: 100
Study 24595780 — intervention group
Group type: COMPARATOR
Intervention: No-acupuncture control
Number of subjects: 100
Study 23431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen (AO) 2 L/min from a portable oxygen concentrator
Number of subjects: 45
Study 23431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR)
Number of subjects: 45
Study 23431028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 20880433 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% proparacaine
Number of subjects: 33
Study 20880433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18251212 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination tablet of an ACE inhibitor (perindopril) with a diuretic (indapamide) (4 mg/l,250 mg)
Number of subjects: 11140
Study 18251212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study 16825335 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 100
Study 16825335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 100
Study 16825335 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 100
Study 12809891 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104
Study 12809891 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study 10678254 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 79
Study 9010691 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPO-PGE1 (50 micrograms bolus injection)
Number of subjects: 20
Study 9010691 — intervention group
Group type: COMPARATOR
Intervention: PGE1-cyclodextrin (60 micrograms infusion over 2 hours)
Number of subjects: 20
Study 1739236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide, 250 mg orally
Number of subjects: 12
Study 1739236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6377891 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg with meals three times daily)
Number of subjects: 18
Study 6377891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6377891 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 18
Study 30128694 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging proton density fat fraction (PDFF) using 27 ROIs
Number of subjects: 45
Study 30128694 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging proton density fat fraction (PDFF) using 9 ROIs
Number of subjects: 45
Study 30128694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis for whole-liver PDFF measurement
Number of subjects: 45
Study 29494790 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in flexible restraint
Number of subjects: 61
Study 29494790 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in rigid restraint
Number of subjects: 61
Study 29494790 — intervention group
Group type: COMPARATOR
Intervention: Disinhibition
Number of subjects: 61
Study 29494790 — intervention group
Group type: COMPARATOR
Intervention: Hunger
Number of subjects: 61
Study 26611571 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and saffron
Number of subjects: 40
Study 26611571 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine and placebo
Number of subjects: 40
Study 25389751 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative approach to education embedding support for self-regulation in literacy, mathematics, and science learning activities.
Number of subjects: 759
Study 22496115 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for vascular access
Number of subjects: 150
Study 22496115 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 20013046 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child reporting discrepancies on measures of child social phobia symptoms
Number of subjects: 81
Study 20013046 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment responder status
Number of subjects: 81
Study 16472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg/20 mg
Number of subjects: 299
Study 16472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg/40 mg
Number of subjects: 299
Study 16472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160 mg/80 mg
Number of subjects: 299
Study 16472588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study 12858201 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT)
Number of subjects: 7
Study 12858201 — intervention group
Group type: COMPARATOR
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 7
Study 12858201 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT with intermediate/advanced disease
Number of subjects: 7
Study 12858201 — intervention group
Group type: EXPERIMENTAL
Intervention: PBSCT with lower proportion of advanced disease
Number of subjects: 7
Study 11187565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Number of subjects: 0
Study 11187565 — intervention group
Group type: COMPARATOR
Intervention: ANOVA
Number of subjects: 0
Study 9604449 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB plus 100 g of calcipotriol (50 micrograms/g) ointment per week
Number of subjects: 0
Study 9604449 — intervention group
Group type: COMPARATOR
Intervention: UVB alone
Number of subjects: 0
Study 9604449 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment alone (100 g/week)
Number of subjects: 0
Study 9604449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (UVB plus calcipotriol)
Number of subjects: 0
Study 8409072 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 327
Study 8409072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 2422467 — intervention group
Group type: EXPERIMENTAL
Intervention: tiapamil 1 mg/kg body weight
Number of subjects: 20
Study 2422467 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 6 micrograms/kg
Number of subjects: 20
Study 2422467 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 15 micrograms/kg
Number of subjects: 20
Study 2422467 — intervention group
Group type: COMPARATOR
Intervention: placebo (20 ml 0.9% NaCl)
Number of subjects: 20
Study 31575503 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m2 and carboplatin (AUC 2 μg×h/mL) on days 1 and 8 (group 1)
Number of subjects: 102
Study 31575503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin plus intravenous trilaciclib 240 mg/m2 on days 1 and 8 (group 2)
Number of subjects: 102
Study 31575503 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and carboplatin on days 2 and 9 plus trilaciclib on days 1, 2, 8, and 9 (group 3)
Number of subjects: 102
Study 28464321 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-3801b 50 mg
Number of subjects: 60
Study 28464321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23556466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-invitation group (food supplements starting at ∼9 weeks gestation, 2.5 MJ d(‐1), 6 days a week)
Number of subjects: 1041
Study 23556466 — intervention group
Group type: COMPARATOR
Intervention: Usual-invitation group (food supplements starting at ∼20 weeks gestation)
Number of subjects: 1041
Study 23114870 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-fit MRI-based pin guides
Number of subjects: 80
Study 23114870 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary alignment jigs
Number of subjects: 80
Study 21341920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group earning monetary vouchers for biochemical samples meeting smoking abstinence criteria
Number of subjects: 2
Study 21341920 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent group earning monetary vouchers independent of smoking status
Number of subjects: 2
Study 21341920 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group with access to bupropion
Number of subjects: 2
Study 21341920 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent group with access to bupropion
Number of subjects: 2
Study 20051716 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rhinovirus infections
Number of subjects: 0
Study 20051716 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rhinoviral wheezing
Number of subjects: 0
Study 20051716 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral infections
Number of subjects: 0
Study 20051716 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune stimulation by rhinovirus infections
Number of subjects: 0
Study 20051716 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of allergen exposure
Number of subjects: 0
Study 17309935 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/vitamin D supplementation (500 mg calcium carbonate with 200 IU vitamin D twice daily)
Number of subjects: 36282
Study 17309935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 15868107 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Educational and Support Group programme (IESG)
Number of subjects: 96
Study 15868107 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants and those not invited to IESG)
Number of subjects: 96
Study 15868107 — intervention group
Group type: EXPERIMENTAL
Intervention: IESG
Number of subjects: 96
Study 15868107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 12184523 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic motilin infusion
Number of subjects: 10
Study 12184523 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 9536937 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment
Number of subjects: 0
Study 9536937 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg/day for one month followed by 20 mg/day for six months
Number of subjects: 0
Study 7634631 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice daily for 7 days postoperatively
Number of subjects: 27
Study 7634631 — intervention group
Group type: COMPARATOR
Intervention: Control (no non-steroidal antiinflammatory drug)
Number of subjects: 27
Study 7634631 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 27
Study 7634631 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 2647711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoloid mesylates
Number of subjects: 10
Study 2647711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 869151 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0‐125% or 0‐25% bupivacaine solutions
Number of subjects: 11
Study 30521366 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized behaviors across a 5-day protocol in dim light
Number of subjects: 26
Study 30521366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior nocturnal sleep
Number of subjects: 26
Study 30521366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior rested wakefulness
Number of subjects: 26
Study 30521366 — intervention group
Group type: COMPARATOR
Intervention: Maintained wakefulness
Number of subjects: 26
Study 28342390 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 80
Study 28342390 — intervention group
Group type: COMPARATOR
Intervention: Aqueous gel
Number of subjects: 80
Study 25941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (mild renal impairment)
Number of subjects: 811
Study 25941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (moderate renal impairment)
Number of subjects: 811
Study 25941160 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin with insulin (severe renal impairment)
Number of subjects: 811
Study 25941160 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin (mild renal impairment)
Number of subjects: 811
Study 25941160 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin (moderate renal impairment)
Number of subjects: 811
Study 25941160 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin (severe renal impairment)
Number of subjects: 811
Study 23465039 — intervention group
Group type: EXPERIMENTAL
Intervention: EBDI tailored to motivational interviewing (MI) technique
Number of subjects: 991
Study 23465039 — intervention group
Group type: COMPARATOR
Intervention: EBDI provided as usual
Number of subjects: 991
Study 22470030 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (β‐carotene, vitamin C, vitamin E)
Number of subjects: 103
Study 22470030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 19567761 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (N=47)
Number of subjects: 100
Study 19567761 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N=53)
Number of subjects: 100
Study 16691463 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based modeling approach for analyzing longitudinal data on substance abuse remission
Number of subjects: 0
Study 15568960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Vision Screener (PVS)
Number of subjects: 40
Study 15568960 — intervention group
Group type: COMPARATOR
Intervention: Control group (adults with binocularity scores >50%)
Number of subjects: 40
Study 11341475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2mg twice daily
Number of subjects: 0
Study 11341475 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin 5mg 3 times daily
Number of subjects: 0
Study 11341475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11341475 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily extended-release tolterodine capsules
Number of subjects: 0
Study 11341475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 0
Study 9022531 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (FOC) 5 g
Number of subjects: 29
Study 9022531 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified eicosapentaenoic acid (EPA) 3 g
Number of subjects: 29
Study 9022531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil ethyl esters) 5 g
Number of subjects: 29
Study 7889665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 24-0238, 10% solution in diethylene glycol monoethyl ether
Number of subjects: 10
Study 7889665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3065929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (CFT) 100 mg/kg once daily
Number of subjects: 70
Study 3065929 — intervention group
Group type: COMPARATOR
Intervention: Combined intramuscular ampicillin (160 mg/kg/day) and chloramphenicol (100 mg/kg/day) given every 6 h (AMC)
Number of subjects: 70
Study 3065929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone (CFT)
Number of subjects: 70
Study 3065929 — intervention group
Group type: COMPARATOR
Intervention: Combined intramuscular ampicillin and chloramphenicol (AMC)
Number of subjects: 70
Study 4947831 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 4947831 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 0
Study 30502416 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus rifampicin
Number of subjects: 60
Study 30502416 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin alone
Number of subjects: 60
Study 30502416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29044488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nail plate replaced after nail-bed repair
Number of subjects: 60
Study 29044488 — intervention group
Group type: COMPARATOR
Intervention: Nail plate discarded after nail-bed repair
Number of subjects: 60
Study 23980523 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 697
Study 23980523 — intervention group
Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 697
Study 23980523 — intervention group
Group type: EXPERIMENTAL
Intervention: rilpivirine
Number of subjects: 697
Study 23980523 — intervention group
Group type: COMPARATOR
Intervention: efavirenz
Number of subjects: 697
Study 22621465 — intervention group
Group type: EXPERIMENTAL
Intervention: New methadone formulation
Number of subjects: 24